1st Dec, 2021

Galnobax® achieves Primary Endpoint in the Phase-3 clinical trial for the treatment of Diabetic Foot Ulcers (DFU)

NovaLead has recently completed Phase-III clinical study of Galnobax® which is its flagship product which is a repurposed drug. The Phase-III trial data analysis shows that the primary as well as secondary endpoint for percentage of subjects achieving complete ulcer closure are met with Galnobax demonstrating statistically significant superiority over the standard of care (SoC). Analysis further showed that Galnobax® demonstrated statistically significant superiority over the standard of care (SoC) in ‘Hard to Heal’ ulcers as well. The safety analysis showed that Galnobax® is safe for long term use.

NovaLead is a drug discovery research company focused on discovering new indications for generic drugs. Enabled by proprietary technology platform, NovaLead's drug repositioning approach is targeted at finding new biological targets for generic drugs, thereby discovering new indication possibilities. This approach is distinctly differentiated from conventional line extension strategies. NovaLead's business development and outsourced research services are managed by its wholly owned subsidiary - Novalead Pharma Inc., USA.

NovaLead's discovery pipeline has an addressable market estimated at over US$ 10 billion p.a. The lead candidate in the pipeline is Galnobax®, which is a topical gel for the treatment of hard to heal Diabetic Foot Ulcer (DFU). The recently concluded Phase – III clinical trial has demonstrated that Galnobax® has successfull met both primary and secondary endpoints for wound closure and is safe for long term use. Given the limitations of existing therapies for DFU, Galnobax® is looked at as a ray of hope by millions of DFU patients worldwide.

Entire discovery research of NovaLead is done in-house and entire biological validation is outsourced to service providers with specific expertise around the world. The commercial model of NovaLead is to outlicense / partner its discoveries after first human proof of concept. Headquartered in Pune - India, NovaLead is funded by top tier venture investors from India and Europe.

Management Team

Supreet Deshpande
Managing Director

Supreet is a founder and visionary behind NovaLead. With an international career of over 23 years in various senior strategic positions... know more

Atul Aslekar

Atul is CTO and co-founder of NovaLead. Atul has over 22 years of experience in technology and operations management... know more

Dr. Sudhir Kulkarni
VP, Discovery

Sudhir has been a backbone of scientific developments at NovaLead. He has been proponent of drug repurposing for past 12 years... know more

Yogini Garud
VP, Finance

Yogini Garud joined NovaLead Pharma on February 1, 2011 as Vice President (Finance) apart from being Head of Finance; she also looks... know more

Kamalakar Jadhav
VP, Technology

Kamalakar has over 16 year experience in the field of computer aided drug design. He has a Masters’ degree from the Interdisciplinary... know more


NovaLead’s research effort is focussed on find new thepaeutics for hard-to-treat diseases and unmet medical needs. NovaLead explores generic drugs to find new indication possibilities in these areas. Such candidates have little chance of failure on account of safety as their safety profile in humans is well documented through historic use for their original indication.Thus eliminating one of the major causes of late stage drug failures. NovaLead's' pipeline has several candidates at different stages of development. The lead compounds in NovaLead's pipeline are given below:


Galnobax® is a topical gel for non healing chronic wounds of diabetics.

Read More

Psoriasis candidate is application of an FDA approved generic drug molecule.

Read More


Galnobax® is a topical gel for non healing chronic wounds. Galnobax® is a repurposed generic drug molecule, which has recently completed Phase- III clinical trial in diabetic foot ulcer (DFU) successfully meeting both primary and secondary endpoints for both, safety and efficacy. The data from Phase III and Phase I/II studies substantiates pre-clinical findings that Galnobax® re-triggers natural wound healing processes impaired due to diabetic condition.

Global DFU challenge

World over, more than 392 million people have Diabetes, expected to rise to 592 million in 2035. About 15% of them suffer from DFU at least once in lifetime, with 25% of DFUs eventually requiring amputation. DFU is a leading cause of lower extremety amputation. Every 20 seconds somewhere in the world, a lower limb is amputated due to DFU. Five year mortality post amputation is 46%. DFU remains a serious disease with very limited drug options and very high cost of treatment.

DFU imposes substantial burden on public and private payers, in the range of US $9-$13 billion in US alone. Due to rising number of diabetics globally, the DFU treatment market is expected to cross US $ 3.5 Billion by 2019.

Globally 392 million people have Diabetes; expected to rise to 592 million in 2035
About 15% of diabetics suffer from DFU at least once in lifetime
About 85% of non traumatic lower extremity amputations are due to DFU


NovaLead has received grant of its patent for NLP91 covering broad set of indications including psoriasis in USA. NovaLead team has discovered novel anti-inflammatory activity for an FDA approved generic drug molecule having potential for inflammatory skin diseases like psoriasis and dermatitis. The discovery of the indication was achieved by extensive use of in-silico RVHTS technologies. A series of experimental validations by in vitro studies also confirmed the activity of the candidate for psoriasis. The candidate NLP91 is under further pre-clinical validations in animal models.

Market for Psoriasis / limitations of existing drugs

Psoriasis is a chronic skin disease that 2-3 % of the global population. It is the most prevalent autoimmune disease in the U.S. with more than 7.5 million Americans affected (~ 2.5% of the population). The disease negatively impacts quality of life for majority of patients. Broad level Psorisis and related market is expected to reach $8.2 Billion in 2020.

Many biologics approved for arthritis are in use for treating severe posiriasis. There are fewer drugs for treating mild-to-moderate psoriasis, which constitute more than 70% of psoriasis cases. Due to limitations of these drugs, there is a dire need for an effective and longer lasting treatment for mild-to-moderate psoriasis.

Psoriasis affects about 125 million people worldwide
As of 2015, annual medical costs for psoriasis are estimated at USD 3.9 billion
Psoriasis has been linked to the depression and suicidal tendencies in patients


The Reverse Virtual High Throughput Screening (RVHTS) blends structure guided and ligand based drug design and screening approaches. It includes methods for flexible receptor-drug docking interaction analysis, molecular shape based similarity identification, molecular fragments to activity relationship studies and active site structure analysis to name a few. Besides this, it employs extensive drug-disease-target knowledgebase which is acompendium of databases of FDA approved drugs, validated drug targets, mechanism of actions for various diseases and the intelligent correlations between these datasets. The platform set up consists of modern multi-core parallel processing cluster which churns millions of molecular simulations to deliver an all inclusive interaction analysis.


NovaLead's' RVHTS technology can be effectively employed for product life cycle management and reviving shelved compounds. It also assists in identifying most appropriate disease for an early stage molecule. NovaLead team either starts with the intended drug molecule or preferred protein target or the disease of interest. If this interests you, please visit us on www.vlifesciences.com


NovaLead believes in the spirit of partnership and collaboration. We are open to explore partnering as well as licensing alternatives. We expect our drug candidates to follow the 505(b)(2) route for FDA filing and similar regulatory paths for EU, Japan and other regulated markets.

Beside the product candidates in our pipeline, we are also open for customer-driven collaboration. We can help you find novel indications of existing drugs, using our proprietary discovery platform.

To know more drop in an e-mail

or give us a call


NovaLead Pharma Pvt. Ltd. announces commencement of double blinded, multicenter Phase-3 study of Galnobax® for Diabetic Foot Ulcer

12 Nov 2018: NovaLead Pharma Pvt. Ltd. announces commencement of double blinded, multicenter Phase-3 study of Galnobax® for Diabetic Foot Ulcer, which is a global unmet medical need. Earlier clinical trials conducted by the company demonstrated promising efficacy and safety of Galnobax® in treating diabetic foot ulcers. Galnobax® is a repurposed generic drug molecule with a long safe history of human use. This Phase-3 human trial being conducted on 350 patients of DFU is partly supported by Grant-In-Aid by the Government of India. The results from trial are expected to be used to support registration and market approval in India and other developing markets.

NovaLead receives "Frost & Sullivan's Indian Drug Repurposing Technology Innovation Leadership Award 2017"

Novalead Pharma has been selected by Frost & Sullivan, leading global industry tracking firm as Best Technology Company in Drug Repositioning for the Year 2017. The award was received by our CEO Mr. Supreet Deshpande in presence of distinguished business and industry leaders in a glittering function held on 05 Oct 2017 at ITC Maratha, Mumbai. Previously in 2015, NovaLead Pharma also received the Best Innovation Company BIRAC award from DBT. Mr. Deshpande’s interview conducted by Frost & Sullivan will be shared in coming days.

NovaLead receives "DBT-BIRAC Innovator Award 2015"

NovaLead team is pleased to inform that the company has been selected for the “BIRAC Innovator Award 2015” from DBT, Govt. of India in recognition of the significant contribution made towards the high level of innovation research for “Determining safety, effective dose and frequency of application of Galnobax®”.

The selection has been made by an eminent Jury set up by the Secretary, DBT & Chairman, BIRAC and the award will be conferred during the Inaugural session of “4th BIRAC Innovators Meet” to be held on 15th – 16th September, 2015, at Heritage Village Resort, Manesar, Gurgaon”.

On this occasion Mr. Supreet Deshpande, CEO said:

"We are delighted at being selected for BIRAC Innovation Award - 2015 in healthcare. This award underlines the national relevance of our investigational drug product Galnobax® for diabetic foot ulcer. It is also a validation for NovaLead's innovative research approach to find new therapeutic products for unmet and hard to treat diseases. I congratulate the entire NovaLead team on this momentous occasion."


NovaLead is an equal opportunity employer with a stimulating work culture that fosters creativity and innovation. At NovaLead, the vision of contributing to a healthy, happy and convenient life for humanity is reflected in the working environment. We firmly believe that freedom of initiative and thinking are the fundamental rights of creative minds to excel in what they do and in what we stand for as a company.

Send your Resumes to careers@novaleadpharma.com


NovaLead Pharma Pvt. Ltd.
2nd and 3rd Floor, Plot No-05,
Next to Sapling Nursery, Ram Indu Park,
Survey No-131/1b/2/11, Baner Road,
Pune 411045, Maharashtra.
Tel : + 91 7066233033
        + 91 8669656660


NovaLead Pharma Inc.
433 South Street
Shrewsbury MA 05415

1375, Broadway
New York NY

NovaLead Pharma Inc.

NovaLead Pharma Inc. is a wholly owned subsidiary of NovaLead Pharma Private Limited, Pune – India (Indian parent company). It is located at 433, South Street, Shrewsbury MA 05415.

Its primary business activities are to manage conduct of:

  1. Phase II B clinical trials for parent company’s discovery, Galnobax® which is a repurposed drug for Diabetic Foot Ulcer. The right to develop this discovery for USA is with Novalead Pharma Inc. The actual clinical trial conduct will be outsourced to third party CRO in USA.

  2. Preclinical studies and subsequently, clinical Phase I/II trial for NLP-91 for Psoriasis in USA. The patent for this discovery is already filed by Novalead Pharma Inc. The actual clinical trial conduct will be outsourced to third party CROs in USA and research labs preferably within MA.

  3. To manage preclinical studies for other candidates in discovery pipeline of the parent company in USA. The actual biological validation will be outsourced to third party research labs preferably within MA.

Galnobax®: India Phase III has commenced in Nov 2018 and the Global Phase II-B is to commence in 2019.
Advance NLP91 for Psoriasis to IND
Manage NovaLead collabration in USA

  1. Patent filings for the Company and its Indian parent company’s discoveries across the world in consultation with Patent attorneys based in USA from time to time. Currently, the company works with Crowell and Moring LLP, Washington DC.

  2. Oversee company’s collaborative research programs with government research institutions and universities in North America.